Benzinga | Nov 11, 2020 04:09PM EST

Cyclacel Pharmaceuticals Q3 EPS $(0.47) Beats $(0.55) Estimate

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.55) by 14.55 percent. This is a 327.27 percent decrease over losses of $(0.11) per share from the same period last year.